Molecular imaging of neuroendocrine tumors

Seminars in Oncology

Volumn 37, Issue 6, 2010, Pages 662-679

  Carrasquillo, Jorge A ^a,b   Chen, Clara C ^c  

^a MEMORIAL SLOAN KETTERING CANCER CENTER   (United States)

^b WEILL CORNELL MEDICAL COLLEGE   (United States)

^c NATIONAL INSTITUTES OF HEALTH   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

(3 IODOBENZYL)GUANIDINE; (3 IODOBENZYL)GUANIDINE I 123; (3 IODOBENZYL)GUANIDINE I 131; 6 FLUORODOPAMINE F 18; CARBIDOPA; CARBON 11; DOPA; FLUORODEOXYGLUCOSE F 18; GALLIUM 68; PENTETREOTIDE IN 111; RECEPTOR SUBTYPE; SEROTONIN; SOMATOSTATIN RECEPTOR; SUCCIMER TC 99M;

ARTICLE; GASTROINTESTINAL TUMOR; HEAD AND NECK TUMOR; HUMAN; LUNG TUMOR; MERKEL CELL TUMOR; MOLECULAR IMAGING; NEUROENDOCRINE TUMOR; NEUROSECRETORY CELL; PANCREAS ISLET CELL TUMOR; PARAGANGLIOMA; PHEOCHROMOCYTOMA; POSITRON EMISSION TOMOGRAPHY; PRIORITY JOURNAL; THYMOMA; THYROID MEDULLARY CARCINOMA; TUMOR DIAGNOSIS; TUMOR SCINTISCANNING;

HUMANS; MOLECULAR IMAGING; NEUROENDOCRINE TUMORS; RADIOPHARMACEUTICALS; SENSITIVITY AND SPECIFICITY;

EID: 78650244299     PISSN: 00937754     EISSN: None     Source Type: Journal    
DOI: 10.1053/j.seminoncol.2010.10.015     Document Type: Article

References (179)

1. A.G.E. Pearse The cytochemistry and ultrastructure of polypeptide hormone-producing cells of the APUD series and the embryologic, physiologic and pathologic implications of the concept J Histochem Cytochem 17 1969 303 313
2. E. Solcia, G. Kloppel, and L.H. Sobin Histological typing of endocrine tumours E. Solcia, G. Kloppel, L.H. Sobin, WHO international histological classification of tumours 2000 Springer Verlag Heidelberg 1 5
3. D.M. Wieland, D.P. Swanson, L.E. Brown, and W.H. Beierwaltes Imaging the adrenal-medulla with an I-131-labeled antiadrenergic agent J Nucl Med 20 1979 155 158
4. L. Kolby, P. Bernhardt, and A.M. Levin-Jakobsen Uptake of meta-iodobenzylguanidine in neuroendocrine tumours is mediated by vesicular monoamine transporters Br J Cancer 89 2003 1383 1388
5. N. Furuta, H. Kiyota, F. Yoshigoe, N. Hasegawa, and Y. Ohishi Diagnosis of pheochromocytoma using [I-123]-compared with [I-131]-metaiodobenzylguanidine scintigraphy Int J Urol 6 1999 119 124
6. E. Bombardieri, C. Aktolun, and R.P. Baum I-131/I-123- metaiodobenzylguanidine (MIBG) scintigraphy: procedure guidelines for tumour imaging Eur J Nucl Med Mol Imaging 30 2003 BP132 BP139
7. D. Hoyer, G.I. Bell, and M. Berelowitz Classification and nomenclature of somatostatin receptors Trends Pharmacol Sci 16 1995 86 88
8. U. Dorr, U. Rath, and M.L. Sautterbihl Improved visualization of carcinoid liver metastases by In-111 pentetreotide scintigraphy following treatment with cold somatostatin analog European J Nucl Med 20 1993 431 433
9. M. Hofmann, H. Maecke, and A.R. Borner Biokinetics and imaging with the somatostatin receptor PET radioligand Ga-68-DOTATOC: preliminary data Eur J Nucl Med 28 2001 1751 1757
10. M. Gabriel, C. Decristoforo, and D. Kendler Ga-68-DOTA-Tyr(3)-octreotide PET in neuroendocrine tumors: comparison with somatostatin receptor scintigraphy and CT J Nucl Med 48 2007 508 518
11. I. Kayani, J.B. Bomanji, and A. Groves Functional Imaging of neuroendocrine tumors with combined PET/CT using Ga-68-DOTATATE (Dota-DPhe(1),Tyr(3)-octreotate) and F-18-FDG Cancer 112 2008 2447 2455
12. A. Haug, C.J. Auernhammer, and B. Wangler Intraindividual comparison of Ga-68-DOTA-TATE and F-18-DOPA PET in patients with well-differentiated metastatic neuroendocrine tumours Eur J Nucl Med Mol Imaging 36 2009 765 770
13. V. Ambrosini, P. Castellucci, and D. Rubello Ga-68-DOTA-NOC: a new PET tracer for evaluating patients with bronchial carcinoid Nucl Med Commun 30 2009 281 286
14. P. Antunes, M. Ginj, H. Zhang, B. Waser, R.P. Baum, J.C. Reubi, and H. Maecke Are radiogallium-labelled DOTA-conjugated somatostatin analogues superior to those labelled with other radiometals? Eur J Nucl Med Mol Imag 34 7 2007 982 993
15. H.R. Maecke, M. Hofmann, and U. Haberkorn Ga-68-labeled peptides in tumor imaging J Nucl Med 46 2005 172S 178S
16. S. Hoegerle, C. Altehoefer, and N. Ghanem Whole-body F-18 dopa PET for detection of gastrointestinal carcinoid tumors Radiology 220 2001 373 380
17. S. Kauhanen, M. Seppanen, and P. Nuutila Premedication with carbidopa masks positive finding of insulinoma and beta-cell hyperplasia in F-18 -dihydroxy-phenyl-alanine positron emission tomography J Clin Oncol 26 2008 5307 5308
18. H. Timmers, M. Hadi, and J.A. Carrasquillo The effects of carbidopa on uptake of 6-F-18-fluoro-L-DOPA in PET of pheochromocytorna and extraadrenal abdominal paraganglioma J Nucl Med 48 2007 1599 1606
19. H. Orlefors, A. Sundin, and U. Garske Whole-body C-11-5-hydroxytryptophan positron emission tomography as a universal imaging technique for neuroendocrine tumors: Comparison with somatostatin receptor scintigraphy and computed tomography J Clin Endocrinol Metab 90 2005 3392 3400
20. K.P. Koopmans, O.C. Neels, and I.P. Kema Improved staging of patients with carcinoid and islet cell tumors with F-18-dihydroxy-phenyl-alanine and C-11-5-hydroxy-tryptophan positron emission tomography J Clin Oncol 26 2008 1489 1495
21. Y.S. Song, W.W. Lee, J.H. Chung, S.Y. Park, Y.K. Kim, and S.E. Kim Correlation between FDG uptake and glucose transporter type 1 expression in neuroendocrine tumors of the lung Lung Cancer 61 2008 54 60
22. D. Delbeke, R.E. Coleman, and M.J. Guiberteau Procedure guideline for tumor imaging with F-18-FDG PET/CT 1.0 J Nucl Med 47 2006 885 895
23. K. Pacak, G. Eisenhofer, J.A. Carrasquillo, C.C. Chen, S.T. Li, and D.S. Goldstein 6-[F-18]fluorodopamine positron emission tomographic (PET) scanning for diagnostic localization of pheochromocytoma Hypertension 38 2001 6 8
24. I. Ilias, J. Yu, and J.A. Carrasquillo Superiority of 6-[F-18]-fluorodopamine positron emission tomography versus [I-131]- metaiodobenzylguanidine scintigraphy in the localization of metastatic pheochromocytoma J Clin Endocrinol Metab 88 2003 4083 4087
25. H. Timmers, C.C. Chen, and J.A. Carrasquillo Comparison of F-18-fluoro-L-DOPA, F-18-fluoro-deoxyglucose, and F-18-fluorodopamine PET and I-123-MIBG scintigraphy in the localization of pheochromocytoma and paraganglioma J Clin Endocrinol Metab 94 2009 4757 4767
26. H. Ohta, K. Yamamoto, and K. Endo A new imaging agent for medullary carcinoma of the thyroid J Nucl Med 25 1984 323 325 (Pubitemid 14152918)
27. D. Denoyer, N. Perek, N. Le Jeune, D. Frere, and F. Dubois Evidence that Tc-99m-(V)-DMSA uptake is mediated by NaPi cotransporter type III in tumour cell lines Eur J Nucl Med Mol Imag 31 2004 77 84
28. J.A. Norton, R.S. Warren, M.G. Kelly, M.B. Zuraek, and R.T. Jensen Aggressive surgery for metastatic liver neuroendocrine tumors Surgery 134 2003 1057 1063
29. M.W. Hanson, J.M. Feldman, R.A. Blinder, J.O. Moore, and R.E. Coleman Carcinoid-tumors - I-131 MIBG scintigraphy Radiology 172 1989 699 703
30. S. Ezziddin, T. Logvinski, and C. Yong-Hing Factors predicting tracer uptake in somatostatin receptor and MIBG scintigraphy of metastatic gastroenteropancreatic neuroendocrine tumors J Nucl Med 47 2006 223 233
31. G. Kaltsas, M. Korbonits, and E. Heintz Comparison of somatostatin analog and meta-iodobenzylguanidine radionuclides in the diagnosis and localization of advanced neuroendocrine tumors J Clin Endocrinol Metab 86 2001 895 902
32. 18F-FDG PET J Nucl Med 51 2010 704 712
33. E.P. Krenning, D.J. Kwekkeboom, and W.H. Bakker Somatostatin receptor scintigraphy with In-111-DTPA-D-PHE(1)- and I-123-TYR(3)-octreotidethe Rotterdam experience with more than 1000 patients Eur J Nucl Med 20 1993 716 731
34. J. Bertherat, F. Tenenbaum, and K. Perlemoine Somatostatin receptors 2 and 5 are the major somatostatin receptors in insulinomas: an in vivo and in vitro study J Clin Endocrinol Metab 88 2003 5353 5360
35. S. Rickes, K. Unkrodt, K. Ocran, H. Neye, and W. Wermke Differentiation of neuroendocrine tumors from other pancreatic lesions by echo-enhanced power Doppler sonography and somatostatin receptor scintigraphy Pancreas 26 2003 76 81
36. O. Schillaci, A. Spanu, and F. Scopinaro Somatostatin receptor scintigraphy in liver metastasis detection from gastroenteropancreatic neuroendocrine tumors J Nucl Med 44 2003 359 368
37. R. Lebtahi, G. Cadiot, and L. Sarda Clinical impact of somatostatin receptor scintigraphy in the management of patients with neuroendocrine gastroenteropancreatic tumors J Nucl Med 38 1997 853 858
38. V. Ambrosini, P. Tomassetti, and P. Castellucci Comparison between Ga-68-DOTA-NOC and F-18-DOPA PET for the detection of gastro-entero-pancreatic and lung neuro-endocrine tumours Eur J Nucl Med Mol Imag 35 2008 1431 1438
39. H. Ahlstrom, B. Eriksson, M. Bergstrom, P. Bjurling, B. Langstrom, and K. Oberg Pancreatic neuroendocrine tumorsdiagnosis with PET Radiology 195 1995 333 337
40. F. Montravers, D. Grahek, and K. Kerrou Can fluorodihydroxyphenylalanine PET replace somatostatin receptor scintigraphy in patients with digestive endocrine tumors? J Nucl Med 47 2006 1455 1462
41. 18F) positron emission tomography on management of adult patients with documented or occult digestive endocrine tumors J Clin Endocrinol Metab 94 2009 1295 1301
42. S. Adams, R.P. Baum, A. Hertel, P.M. Schumm-Drager, K.H. Usadel, and G. Hor Metabolic (PET) and receptor (SPET) imaging of well- and less well-differentiated tumours: comparison with the expression of the Ki-67 antigen Nucl Med Commun 19 1998 641 647
43. C. Pasquali, D. Rubello, and C. Sperti Neuroendocrine tumor imaging: can F-18-fluorodeoxyglucose positron emission tomography detect tumors with poor prognosis and aggressive behavior? World J Surg 22 1998 588 592
44. M.R. Clarke, E.E. Baker, R.J. Weyant, L. Hill, and S.E. Carty Proliferative activity in pancreatic endocrine tumors: Association with function, metastases, and survival Endocr Pathol 8 1997 181 187
45. E. Garin, F. Le Jeune, and A. Devillers Predictive value of F-18-FDG PET and somatostatin receptor scintigraphy in patients with metastatic endocrine tumors J Nucl Med 50 2009 858 864
46. T. Belhocine, J. Foidart, P. Rigo, F. Najjar, A. Thiry, P. Quatresooz, and R. Hustinx Fluorodeoxyglucose positron emission tomography and somatostatin receptor scintigraphy for diagnosing and staging carcinoid tumours: correlations with the pathological indexes p53 and Ki-67 Nucl Med Commun 23 2002 727 734
47. F.J. Service, M.M. McMahon, P.C. Obrien, and D.J. Ballard Functioning insulinomaincidence, recurrence, and long-term survival of patientsa 60-year study Mayo Clin Proc 66 1991 711 719
48. H. Gouya, O. Vignaux, and J. Augui CT, endoscopic sonography, and a combined protocol for preoperative evaluation of pancreatic insulinomas Am J Roentgenol 181 2003 987 992
49. O. Schillaci, R. Massa, and F. Scopinaro In-111-pentetreotide scintigraphy in the detection of insulinomas: Importance of SPECT imaging J Nucl Med 41 2000 459 462
50. S. Kauhanen, M. Seppanen, and H. Minn Fluorine-18-L- dihydroxyphenylalanine (F-18-DOPA) positron emission tomography as a tool to localize an insulinoma or beta-cell hyperplasia in adult patients J Clin Endocrinol Metab 92 2007 1237 1244
51. L. Tessonnier, F. Sebag, and C. Ghander Limited value of 18F-F-DOPA PET to localize pancreatic insulin-secreting tumors in adults with hyperinsulinemic hypoglycemia J Clin Endocrinol Metab 95 2010 303 307
52. H.C. Weber, D.J. Venzon, and J.T. Lin Determinants of metastatic rate and survival in patients with Zollinger-Ellison syndromea prospective long-term study Gastroenterology 108 1995 1637 1649
53. M. Papotti, M. Bongiovanni, and M. Volante Expression of somatostatin receptor types 1-5 in 81 cases of gastrointestinal and pancreatic endocrine tumorsa correlative immunohistochemical and reverse-transcriptase polymerase chain reaction analysis Virchows Arch 440 2002 461 475
54. F. Gibril, J.C. Reynolds, and J.L. Doppman Somatostatin receptor scintigraphy: Its sensitivity compared with that of other imaging methods in detecting primary and metastatic gastrinomasa prospective study Ann Intern Med 125 1996 26
55. E. de Kerviler, G. Cadiot, R. Lebtahi, M. Faraggi, D. Leguludec, and M. Mignon Somatostatin receptor scintigraphy in 48 patients with the Zollinger-Ellison syndrome Eur J Nucl Med 21 1994 1191 1197 (Pubitemid 24336062)
56. G. Cadiot, R. Lebtahi, and L. Sarda Preoperative detection of duodenal gastrinomas and peripancreatic lymph nodes by somatostatin receptor scintigraphy Gastroenterology 111 1996 845 854
57. B. Termanini, F. Gibril, and J.C. Reynolds Value of somatostatin receptor scintigraphy: a prospective study in gastrinoma of its effect on clinical management Gastroenterology 112 1997 335 347
58. F. Gibril, and R.T. Jensen Comparative analysis of diagnostic techniques for localization of gastrointestinal neuroendocrine tumors Yale J Biol Med 70 1997 509 522
59. G. Cadiot, G. Bonnaud, and R. Lebtahi Usefulness of somatostatin receptor scintigraphy in the management of patients with Zollinger-Ellison syndrome Gut 41 1997 107 114 (Pubitemid 27351649)
60. G.C. Nikou, C. Toubanakis, P. Nikolaou, E. Giannatou, M. Safioleas, and E. Mallas VIPomas: an update in diagnosis and management in a series of 11 patients Hepatogastroenterology 52 2005 1259 1265
61. H. Kindmark, A. Sundin, and D. Granberg Endocrine pancreatic tumors with glucagon hypersecretion: a retrospective study of 23 cases during 20 years Med Oncol 24 2007 330 337
62. E. Vauleon, J. Egreteau, E. Boucher, V. DesFourneaux, J.F. Bretagne, and J.L. Raoul Glucagonoma: a recent series of 7 cases Bull Cancer 91 2004 637 640
63. S. Nishiguchi, S. Shiomi, and H. Ishizu A case of glucagonoma with high uptake on F-18 fluorodeoxyglucose positron emission tomography Ann Nucl Med 15 2001 259 262 (Pubitemid 32679222)
64. O. Schillaci, B. Annibale, F. Scopinaro, G. DelleFave, and A.C. Colella Somatostatin receptor scintigraphy of malignant somatostatinoma with indium-111-pentetreotide J Nucl Med 38 1997 886 887
65. S. Angeletti, V.D. Corleto, and O. Schillaci Use of the somatostatin analogue octreotide to localise and manage somatostatin-producing tumours Gut 42 1998 792 794
66. H. Suzuhi, H. Kuwano, N. Masuda, S. Hashimoto, K. Kanoh, K. Nomoto, T. Shimura, and H. Katoh Diagnostic usefulness of FDG-PET for malignant somatostatinoma of the pancreas Hepatogastroenterology 55 2008 1242 1245
67. R. Libe, and P. Chanson Endocrine tumors of the pancreas (EPTs) in multiple endocrine neoplasia (MEN1): up-date on prognostic factors, diagnostic procedures and treatment Ann Endocrinol 68 2007 S1 S8
68. G.C. Nikou, C. Toubanakis, and P. Nikolaou Gastrinomas associated with MEN-1 syndrome: new insights for the diagnosis and management in a series of 11 patients Hepatogastroenterology 52 2005 1668 1676
69. S.K. Libutti, P.L. Choyke, and D.L. Bartlett Pancreatic neuroendocrine tumors associated with vonHippel Lindau disease: diagnostic and management recommendations Surgery 124 1998 1153 1159
70. O. Corcos, A. Couvelard, and S. Giraud Endocrine pancreatic tumors in von Hippel-Lindau diseaseclinical, histological, and genetic features Pancreas 37 2008 85 93
71. M. Falconi, U. Plockinger, and D.J. Kwekkeboom Well-differentiated pancreatic nonfunctioning tumors/carcinoma Neuroendocrinology 84 2006 196 211
72. V.E. Gould, R.I. Linnoila, V.A. Memoli, and W.H. Warren Neuroendocrine cells and neuroendocrine neoplasms of the lung Pathol Ann 18 1983 287 330
73. I.M. Modlin, and A. Sandor An analysis of 8305 cases of carcinoid tumors Cancer 79 1997 813 829
74. E.M. Bertino, P.D. Confer, J.E. Colonna, P. Ross, and G.A. Otterson Pulmonary neuroendocrine/carcinoid tumors Cancer 115 2009 4434 4441
75. M.B. Beasley, E. Brambilla, and W.D. Travis The 2004 World Health Organization classification of lung tumors Semin. Roentgenol 40 2005 90 97
76. A. Yellin, S.T. Zwas, J. Rozenman, D.A. Simansky, and E. Goshen Experience with somatostatin receptor scintigraphy in the management of pulmonary carcinoid tumors Isr Med Assoc J 7 2005 712 716
77. M. Musi, R.G. Carbone, and C. Bertocchi Bronchial carcinoid tumours: a study on clinicopathological features and role of octreotide scintigraphy Lung Cancer 22 1998 97 102
78. D. Granberg, A. Sundin, E.T. Janson, K. Oberg, B. Skogseid, and J.E. Westlin Octreoscan in patients with bronchial carcinoid tumours Clin Endocrinol 59 2003 793 799
79. S. Fanti, M. Farsad, and G. Battista Somatostatin receptor scintigraphy for bronchial carcinoid follow-up Clin Nucl Med 28 2003 548 552 (Pubitemid 38281918)
80. I. Kayani, B.G. Conry, A.M. Groves, T. Win, J. Dickson, M. Caplin, and J.B. Bomanji A comparison of Ga-68-DOTATATE and F-18-FDG PET/CT in pulmonary neuroendocrine tumors J Nucl Med 50 2009 1927 1932
81. J.J. Erasmus, H.P. McAdams, E.F. Patz, R.E. Coleman, V. Ahuja, and P.C. Goodman Evaluation of primary pulmonary carcinoid tumors using FDG PET Am J Roentgenol 170 1998 1369 1373
82. S.M. Chong, K.S. Lee, and B.T. Kim Integrated PET/CT of pulmonary neuroendocrine tumors: diagnostic and prognostic implications Am J Roentgenol 188 2007 1223 1231
83. S. Kruger, A.K. Buck, and N.M. Blumstein Use of integrated FDG PET/CT imaging in pulmonary carcinoid tumours J Intern Med 260 2006 545 550
84. C.E. Daniels, V.J. Lowe, M.C. Aubry, M.S. Allen, and J.R. Jett The utility of fluorodeoxyglucose positron emission tomography in the evaluation of carcinoid tumors presenting as pulmonary nodules Chest 131 2007 255 260
85. T. Jacob, D. Grahek, and N. Younsi Positron emission tomography with F-18 FDOPA and F-18 FDG in the imaging of small cell lung carcinoma: preliminary results Eur J Nucl Med Mol Imag 30 2003 1266 1269
86. O. Tiffet, A.G. Nicholson, G. Ladas, M.N. Sheppard, and P. Goldstraw A clinicopathologic study of 12 neuroendocrine tumors arising in the thymus Chest 124 2003 141 146
87. F. Gibril, Y.J. Chen, and D.S. Schrump Prospective study of thymic carcinoids in patients with multiple endocrine neoplasia type 1 J Clin Endocrinol Metab 88 2003 1066 1081 (Pubitemid 36337758)
88. P. Ferolla, A. Falchetti, and P. Filosso Thymic neuroendocrine carcinoma (carcinoid) in multiple endocrine neoplasia type 1 syndrome: the Italian series J Clin Endocrinol Metab 90 2005 2603 2609
89. B.P. Hauffa, F. Ruhr, and W.S. Liu Ga-68 DOTATOC positron emission tomography (PET) signal intensity is positively correlated with somatostatin receptor (ssr) 2 expression in an ACTH-producing thymic carcinoid tumor causing severe Cushing's syndrome in an adolescent boy Exp Clin Endocrinol Diabetes 115 2007 N4
90. A.M. Groves, H.K. Mohan, E.A. Wegner, S.F. Hain, J.B. Bingham, and S.E.M. Clarke Positron emission tomography with FDG to show thymic carcinoid Am J Roentgenol 182 2004 511 513
91. H.P. Xu, M. Zhang, G. Zhai, G. Ning, and B.A. Li The role of integrated F-18-FDG PET/CT in identification of ectopic ACTH secretion tumors Endocrine 36 2009 385 391
92. L.L. Travaini, G. Petralia, and G. Trifiro F-18 FDG positron emission tomography/computed tomography and multidetector computed tomography roles in thymic lesion treatment planning Lung Cancer 61 2008 362 368
93. T. Hirano, H. Otake, N. Watanabe, N. Oriuchi, A. Zennyouji, T. Fukuda, and K. Endo Presurgical diagnosis of a primary carcinoid-tumor of the thymus with MIBG J Nucl Med 36 1995 2243 2245
94. D. Whitaker, and P. Dussek PET scanning in thymic neuroendocrine tumors Chest 125 2004 2368 2369
95. D.J. Marsh, D.L. Learoyd, and B.G. Robinson Medullary-thyroid carcinomarecent advances and management update Thyroid 5 1995 407 424
96. M.F. Saad, N.G. Ordonez, R.K. Rashid, J.J. Guido, C.S. Hill, R.C. Hickey, and N.A. Samaan Medullary carcinoma of the thyroida study of the clinical-features and prognostic factors in 161 patients Medicine 63 1984 319 342
97. G. Vitale, M. Caraglia, A. Ciccarelli, G. Lupoli, A. Abbruzzese, and P. Tagliaferri Current approaches and perspectives in the therapy of medullary thyroid carcinoma Cancer 91 2001 1797 1808
98. R. Cohen, J.M. Campos, and C. Salaun Preoperative calcitonin levels are predictive of tumor size and postoperative calcitonin normalization in medullary thyroid carcinoma J Clin Endocrinol Metab 85 2000 919 922
99. K. Frankraue, F. Raue, H.J. Buhr, G. Baldauf, D. Lorenz, and R. Ziegler Localization of occult persisting medullary-thyroid carcinoma before microsurgical reoperationhigh-sensitivity of selective venous catheterization Thyroid 2 1992 113 117
100. A.L. Giraudet, D. Vanel, and S. Leboulleux Imaging medullary thyroid carcinoma with persistent elevated calcitonin levels J Clin Endocrinol Metab 92 2007 4185 4190
101. U. Dorr, S. Wurstlin, and K. Frankraue Somatostatin receptor scintigraphy and magnetic-resonance-imaging in recurrent medullary-thyroid carcinomaa comparative-study Hormone Metab Res 27 1993 48 55
102. Q. Wang, S. Takashima, H. Fukuda, F. Takayama, S. Kobayashi, and S. Sone Detection of medullary thyroid carcinoma and regional lymph node metastases by magnetic resonance imaging Arch Otolaryngol Head Neck Surg 125 1999 842 848
103. M. Papotti, U. Kumar, M. Volante, C. Pecchioni, and Y.C. Patel Immunohistochemical detection of somatostatin receptor types 1-5 in medullary carcinoma of the thyroid Clin Endocrinol 54 2001 641 649
104. S. Adams, P. Acker, M. Lorenz, E. Staib-Sebler, and G. Hor Radioisotope-guided surgery in patients with pheochromocytoma and recurrent medullary thyroid carcinomaa comparison of preoperative and intraoperative tumor localization with histopathologic findings Cancer 92 2001 263 270
105. A. Faggiano, F. Grimaldi, and L. Pezzullo Secretive and proliferative tumor profile helps to select the best imaging technique to identify postoperative persistent or relapsing medullary thyroid cancer Endocr Relat Cancer 16 2009 225 231
106. B.G. Conry, N.D. Papathanasiou, and V. Prakash Comparison of Ga-68-DOTATATE and F-18-fluorodeoxyglucose PET/CT in the detection of recurrent medullary thyroid carcinoma Eur J Nucl Med Mol Imag 37 2010 49 57
107. L. Bodei, D. Handkiewicz-Junak, and C. Grana Receptor radionuclide therapy with Y-90-DOTATOC in patients with medullary thyroid carcinomas Cancer Biother Radiopharmaceut 19 2004 65 71
108. S.C. Ong, H. Schoder, and S.G. Patel Diagnostic accuracy of F-18-FDG PET in restaging patients with medullary thyroid carcinoma and elevated calcitonin levels J Nucl Med 48 2007 501 507
109. D. Rubello, L. Rampin, and C. Nanni The role of F-18-FDG PET/CT in detecting metastatic deposits of recurrent medullary thyroid carcinoma: a prospective study Eur J Surg Oncol 34 2008 581 586
110. Z. Szakall, O. Esik, and G. Bajzik F-18-FDG PET detection of lymph node metastases in medullary thyroid carcinoma J Nucl Med 43 2002 66 71
111. A. Oudoux, P.Y. Salaun, and C. Bournaud Sensitivity and prognostic value of positron emission tomography with F-18-fluorodeoxyglucose and sensitivity of immunoscintigraphy in patients with medullary thyroid carcinoma treated with anticarcinoembryonic antigen-targeted radioimmunotherapy J Clin Endocrinol Metab 92 2007 4590 4597
112. S. Hoegerle, C. Altehoefer, N. Ghanem, I. Brink, E. Moser, and E. Nitzsche F-18-DOPA positron emission tomography for tumour detection in patients with medullary thyroid carcinoma and elevated calcitonin levels Eur J Nucl Med 28 2001 64 71
113. M. Beheshti, S. Pocher, and R. Vali The value of F-18-DOPA PET-CT in patients with medullary thyroid carcinoma: comparison with F-18-FDG PET-CT Eur Radiol 19 2009 1425 1434
114. B. Beuthien-Baumann, A. Strumpf, J. Zessin, J. Bredow, and J. Kotzerke Diagnostic impact of PET with F-18-FDG, F-18-DOPA and 3-O-methyl-6- F-18 fluoro-DOPA in recurrent or metastatic medullary thyroid carcinoma Eur J Nucl Med Mol Imag 34 2007 1604 1609
115. M. Diehl, J.H. Risse, and K. Brandt-Mainz Fluorine-18 fluorodeoxyglucose positron emission tomography in medullary thyroid cancer: results of a multicentre study Eur J Nucl Med 28 2001 1671 1676
116. M. Gotthardt, A. Battman, and H. Hoffken F-18-FDG PET, somatostatin receptor scintigraphy, and CT in metastatic medullary thyroid carcinoma: a clinical study and an analysis of the literature Nucl Med Commun 25 2004 439 443
117. J.W.B. de Groot, T.P. Links, P.L. Jager, T. Kahraman, and J.T.M. Plukker Impact of F-18-fluoro-2-deoxy-D-glucose positron emission tomography (FDG-PET) in patients with biochemical evidence of recurrent or residual medullary thyroid cancer Ann Surg Oncol 11 2004 786 794
118. H. Medina-Franco, M.M. Urist, J. Fiveash, M.J. Heslin, K.I. Bland, and S.W. Beenken Multimodality treatment of Merkel cell carcinoma: case series and literature review of 1024 cases Ann Surg Oncol 8 2001 204 208
119. P.J. Allen, W.B. Bowne, D.P. Jaques, M.F. Brennan, K. Busam, and D.G. Coit Merkel cell carcinoma: prognosis and treatment of patients from a single institution J Clin Oncol 23 2005 2300 2309
120. M.J. Gollub, D.R. Gruen, and D.D. Dershaw Merkel cell carcinoma: CT findings in 12 patients Am J Roentgenol 167 1996 617 620
121. S.G. Gupta, L.C. Wang, P.F. Penas, M. Gellenthin, S.J. Lee, and P. Nghiem Sentinel lymph node biopsy for evaluation and treatment of patients with Merkel cell carcinomaThe Dana-Farber experience and meta-analysis of the literature Arch Dermatol 142 2006 685 690
122. N. Watanabe, M. Shimizu, M. Kageyama, K. Kitagawa, S. Hayasaka, and H. Seto I-123-MIBG SPECT of Merkel cell carcinoma Br J Radiol 71 1998 886 887
123. D.J. Kwekkeboom, A.M. Hoff, S.W.J. Lamberts, H.Y. Oei, and E.P. Krenning Somatostatin analog scintigraphya simple and sensitive method for the invivo visualization of Merkel cell tumors and their metastases Arch Dermatol 128 1992 818 821
124. B.K. Durani, A. Klein, M. Henze, U. Haberkorn, and W. Hartschuh Somatostatin analogue scintigraphy in Merkel cell tumours Br J Dermatol 148 2003 1135 1140
125. P. Guitera-Rovel, J. Lumbroso, and M.S. Gautier-Gougis Indium-111 octreotide scintigraphy of Merkel cell carcinomas and their metastases Ann Oncol 12 2001 807 811
126. M. Cimitan, A. Buonadonna, and R. Cannizzaro Somatostatin receptor scintigraphy versus chromogranin A assay in the management of patients with neuroendocrine tumors of different types: clinical role Ann Oncol 14 2003 1135 1141
127. G. Meier, C. Waldherr, R. Herrmann, H. Maecke, J. Mueller-Brand, and M. Pless Successful targeted radiotherapy with Y-90-DOTATOC in a patient with Merkel cell carcinomaa case report Oncology 66 2004 160 163
128. T. Belhocine, G.E. Pierard, and J. Fruhling Clinical added-value of 18FDG PET in neuroendocrine-Merkel cell carcinoma Oncol. Rep 16 2006 347 352
129. R. Concannon, G.S. Larcos, and M. Veness The impact of F-18-FDG PET-CT scanning for staging and management of Merkel cell carcinoma: results from Westmead Hospital, Sydney, Australia J Am Acad Dermatol 62 2010 76 84
130. R.K. Grewal, N. Pandit-Taskar, M. Gonen, and S.M. Larson FDG PET for evaluation of Merkel cell carcinoma [abstract 137] J Nucl Med Suppl 2 2005 46
131. A. Iagaru, A. Quon, I.R. McDougall, and S.S. Gambhir Merkel cell carcinoma: is there a role for 2-deoxy-2- F-18 fluoro-D-glucose-positron emission tomography/computed tomography? Mol Imag Biol 8 2006 212 217
132. P. Peloschek, C. Novotny, and C. Mueller-Mang Diagnostic imaging in Merkel cell carcinoma: lessons to learn from 16 cases with correlation of sonography, CT, MRI and PET Eur J Radiol 73 2010 317 323
133. J.N. Talbot, K. Kerrou, and F. Missoum 6- F-18 fluoro-L-DOPA positron emission tomography in the imaging of Merkel cell carcinoma: preliminary report of three cases with 2-deoxy-2- F-18 fluoro-D-glucose positron emission tomography or pentetreotide-(111ln) SPECT data Mol Imag Biol 7 2005 257 261
134. A.S. Tischler, N. Kimura, and A.M. McNicol Pathology of pheochromocytoma and extra-adrenal paraganglioma Ann NY Acad Sci 1073 2006 557 570
135. H. Timmers, A. Kozupa, and C.C. Chen Superiority of fluorodeoxyglucose positron emission tomography to other functional imaging techniques in the evaluation of metastatic SDHB-associated pheochromocytoma and paraganglioma J Clin Oncol 25 2007 2262 2269
136. B. Shapiro, J.E. Copp, J.C. Sisson, P.L. Eyre, J. Wallis, and W.H. Beierwaltes I-131 metaiodobenzylguanidine for the locating of suspected pheochromocytomaexperience in 400 cases J Nucl Med 26 1985 576 585
137. F. Lumachi, A. Tregnaghi, and P. Zucchetta Sensitivity and positive predictive value of CT, MRI and I-123-MIBG scintigraphy in localizing pheochromocytomas: a prospective study Nucl Med Commun 27 2006 583 587
138. P.D. Mozley, C.K. Kim, J. Mohsin, A. Jatlow, E. Gosfield, and A. Alavi The efficacy of iodine-123-MIBG as a screening-test for pheochromocytoma J Nucl Med 35 1994 1138 1144
139. P. Kaji, J.A. Carrasquillo, and W.M. Linehan The role of 6-[F-18]fluorodopamine positron emission tomography in the localization of adrenal pheochromocytoma associated with von Hippel-Lindau syndrome Eur J Endocrinol 156 2007 483 487
140. I. Ilias, C.C. Chen, and J.A. Carrasquillo Comparison of 6-(18) F-Fluorodopamine PET with I-123-metaiodobenzylguanidine and In-111-pentetreotide scintigraphy in localization of nonmetastatic and metastatic pheochromocytoma J Nucl Med 49 2008 1613 1619
141. H. Timmers, G. Eisenhofer, and J.A. Carrasquillo Use of 6- F-18 -fluorodopamine positron emission tomography (PET) as first-line investigation for the diagnosis and localization of non-metastatic and metastatic phaeochromocytoma (PHEO) Clin Endocrinol 71 2009 11 17
142. B.L. Shulkin, N.W. Thompson, B. Shapiro, I.R. Francis, and J.C. Sisson Pheochromocytomas: imaging with 2-[fluorine-18] fluoro-2-deoxy-D-glucose PET Radiology 212 1999 35 41
143. D.R. Arnold, V.L. Willemagne, C. Civelek, R.F. Dannals, H.N. Wagner, and R. Udelsman FDG-PET: a sensitive tool for the localization of MIBG-negative pelvic pheochromocytomas Endocrinologist 8 1998 295 298
144. S. Hoegerle, E. Nitzsche, and C. Altehoefer Pheochromocytomas: detection with F-18 DOPA whole-body PETinitial results Radiology 222 2002 507 512
145. S. Kauhanen, M. Seppanen, and J. Ovaska The clinical value of F-18 fluoro-dihydroxyphenylalanine positron emission tomography in primary diagnosis, staging, and restaging of neuroendocrine tumor Endocr Relat Cancer 16 2009 255 265
146. D. Taieb, F. Sebag, and A. Barlier F-18-FDG avidity of pheochromocytomas and paragangliomas: a new molecular imaging signature? J Nucl Med 50 2009 711 717
147. C.M. Drovdlic, E.N. Myers, and J.A. Peters Proportion of heritable paraganglioma cases and associated clinical characteristics Laryngoscope 111 2001 1822 1827
148. A.P.G. Vangils, A.G.L. Vandermey, and R. Hoogma Iodine-123- metaiodobenzylguanidine scintigraphy in patients with chemodectomas of the head and neck region J Nucl Med 31 1990 1147 1155
149. A. Bustillo, F. Telischi, and D. Weed Octreotide scintigraphy in the head and neck Laryngoscope 114 2004 434 440
150. D.J. Kwekkeboom, H. Vanurk, and B.K.H. Pauw Octreotide scintigraphy for the detection of paragangliomas J Nucl Med 34 1993 873 878
151. K.P. Koopmans, P.L. Jager, I.P. Kema, M.N. Kersten, F. Albers, and R.P.F. Dullaart In-111-octreotide is superior to I-123-metaiodobenzylguanidine for scintigraphic detection of head and neck paragangliomas J Nucl Med 49 2008 1232 1237
152. R. Milardovic, E.P.M. Corssmit, and M. Stokkel Value of I-123-MIBG scintigraphy in paraganglioma Neuroendocrinology 91 2010 94 100
153. S. Hoegerle, N. Ghanem, and C. Altehoefer F-18-DOPA positron emission tomography for the detection of glomus tumours Eur J Nucl Med Mol Imag 30 2003 689 694
154. D.J. Macfarlane, B.L. Shulkin, K. Murphy, and G.T. Wolf FDG PET imaging of paragangliomas of the neckcomparison with MIBG SPET Eur J Nucl Med 22 1995 1347 1350
155. D.Y. Greenblatt, Y. Shenker, and H. Chen The utility of metaiodobenzylguanidine (MIBG) scintigraphy in patients with pheochromocytoma Ann Surg Oncol 15 2008 900 905
156. J. Miskulin, B.L. Shulkin, G.M. Doherty, J.C. Sisson, R.E. Burney, and P.G. Gauger Is preoperative iodine 123 meta-iodobenzylguanidine scintigraphy routinely necessary before initial adrenalectomy for pheochromocytoma? Surgery 134 2003 918 922
157. M. NocaudieCalzada, D. Huglo, B. Carnaille, G. Proye, and X. Marchandise Comparison of somatostatin analogue and metaiodobenzylguanidine scintigraphy for the detection of carcinoid tumours Eur J Nucl Med 23 1996 1448 1454
158. J.K. Ramage, R. Williams, and M. BuxtonThomas Imaging secondary neuroendocrine tumours of the liver: comparison of I-123 metaiodobenzylguanidine (MIBG) and In-111-labelled octreotide (Octreoscan) QJM Monthly J Assoc Physicians 89 1996 539 542
159. O. Schillaci, A. Spanu, and F. Scopinaro Somatostatin receptor scintigraphy with In-111-pentetreotide in non-functioning gastroenteropancreatic neuroendocrine tumors Int J Oncol 23 2003 1687 1695
160. R. Lebtahi, G. Cadiot, and N. Delahaye Detection of bone metastases in patients with endocrine gastroenteropancreatic tumors: bone scintigraphy compared with somatostatin receptor scintigraphy J Nucl Med 40 1999 1602 1608
161. C. Dromain, T. de Baere, and J. Lumbroso Detection of liver metastases from endocrine tumors: a prospective comparison of somatostatin receptor scintigraphy, computed tomography, and magnetic resonance imaging J Clin Oncol 23 2005 70 78
162. G.C. Nikou, N.J. Lygidakis, and C. Toubanakis Current diagnosis and treatment of gastrointestinal carcinoids in a series of 101 patients: the significance of serum chromogranin-A, somatostatin receptor scintigraphy and somatostatin analogues Hepatogastroenterology 52 2005 731 741
163. F. Panzuto, M. Falconi, and S. Nasoni Staging of digestive endocrine tumours using helical computed tomography and somatostatin receptor scintigraphy Ann Oncol 14 2003 586 591
164. V. Ambrosini, P. Tomassetti, and D. Rubello Role of F-18-dopa PET/CT imaging in the management of patients with In-111-pentetreotide negative GEP tumours Nucl Med Commun 28 2007 473 477
165. K.P. Koopmans, E.G.E. De Vries, and I.P. Kerna Staging of carcinoid tumours with F-18-DOPA PET: a prospective, diagnostic accuracy study Lancet Oncol 7 2006 728 734
166. S. Adams, R. Baum, T. Rink, P.M. Schumm-Drager, K.H. Usadel, and G. Hor Limited value of fluorine-18 fluorodeoxyglucose positron emission tomography for the imaging of neuroendocrine tumours Eur J Nucl Med 25 1998 79 83
167. S. Koukouraki, L.G. Strauss, V. Georgoulias, M. Eisenhut, U. Haberkorn, and A. Dimitrakopoulou-Strauss Comparison of the pharmacokinetics of Ga-68-DOTATOC and [F-18]FDG in patients with metastatic neuroendocrine tumours scheduled for Y-90-DOTATOC therapy Eur J Nucl Med Mol Imag 33 2006 1115 1122
168. L. Troncone, V. Rufini, P. Montemaggi, F.M. Danza, A. Lasorella, and R. Mastrangelo The diagnostic and therapeutic utility of radioiodinated metaiodobenzylguanidine (MIBG)5 years of experience Eur J Nucl Med 16 1990 325 335
169. S.E.M. Clarke, C.R. Lazarus, P. Wraight, C. Sampson, and M.N. Maisey Pentavalent Tc-99m DMSA, I-131 MIBG, and Tc-99m MDPAn evaluation of 3 imaging techniques in patients with medullary carcinoma of the thyroid J Nucl Med 29 1988 33 38
170. K. Frankraue, H. Bihl, U. Dorr, H. Buhr, R. Ziegler, and F. Raue Somatostatin receptor imaging in persistent medullary-thyroid carcinoma Clin Endocrinol 42 1995 31 37
171. A. Kurtaran, C. Scheuba, and K. Kaserer Indium-111-DTPA-D-Phe-1- octreotide and technetium-99m-(V)-dimercaptosuccinic acid scanning in the preoperative staging of medullary thyroid carcinoma J Nucl Med 39 1998 1907 1909
172. E. van der Harst, W.W. de Herder, and H.A. Bruining [I-123] metaiodobenzylguanidine and [In-111]octreotide uptake in benign and malignant pheochromocytomas J Clin Endocrinol Metab 86 2001 685 693
173. H.B. Fiebrich, A.H. Brouwers, and M.N. Kerstens 6- F-18 fluoro-l-dihydroxyphenylalanine positron emission tomography is superior to conventional imaging with I-123-metaiodobenzylguanidine scintigraphy, computer tomography, and magnetic resonance imaging in localizing tumors causing catecholamine excess J Clin Endocrinol Metab 94 2009 3922 3930
174. F. Imani, V.G. Agopian, and M.S. Auerbach F-18-FDOPA PET and PET/CT accurately localize pheochromocytomas J Nucl Med 50 2009 513 519
175. M. Luster, W. Karges, and K. Zeich Clinical value of F-18- fluorodihydroxyphenylalanine positron emission tomography/computed tomography (F-18-DOPA PET/CT) for detecting pheochromocytoma Eur J Nucl Med Mol Imag 37 2010 484 493
176. D. Taieb, L. Tessonnier, and F. Sebag The role of F-18-FDOPA and F-18-FDG-PET in the management of malignant and multifocal phaeochromocytomas Clin Endocrinol 69 2008 580 586
177. D. Taieb, L. Tessonnier, and O. Mundler Positron emission tomography in digestive neuroendocrine tumors: choice of the tracer Med Nucl Imag Fonction Metabol 33 2009 712 717
178. D. Erickson, Y.C. Kudva, and M.J. Ebersold Benign paragangliomas: clinical presentation and treatment outcomes in 236 patients J Clin Endocrinol Metab 86 2001 5210 5216
179. M. Schmidt, E. Fischer, and M. Dietlein Clinical value of somatostatin receptor imaging in patients with suspected head and neck paragangliomas Eur J Nucl Med Mol Imag 29 2002 1571 1580